Richard Cherlin, MD
Endocrinology, Diabetes & Metabolism · Los Gatos, CANPI 1922060219
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $14,956 of the $16,904 with a category attached, or 88.5%. It is spread thinly across 54 manufacturers, the largest accounting for just 11.9% — the pattern of someone who eats at a lot of different presentations.
Across 839 payments — averaging $20.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Lilly USA, LLC$2K
- Acella Pharmaceuticals, LLC$1K
- Abbott$1K
- Amgen$1K
- Antares Pharma, Inc.$842
- plus $9K from 48 others
Across 160 payments — averaging $1222.56 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$44K
- Regeneron$41K
- Kowa Research Institute, Inc.$35K
- Boehringer Ingelheim$31K
- Ascendis Pharma Endocrinology Inc$12K
- Chiasma, Inc.$10K
- plus $23K from 5 others
What the payments were for
- Speaking & faculty fees$1,68510%
- Food & beverage$14,95688%
- Education$2041%
- Gifts$590%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NP Thyroid 60$1,185
- FREESTYLE LIBRE 3$293
How this compares
$16,904 in reported general payments places this provider in the 85th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 337 | $392,454 |
| OzempicSemaglutide | 306 | $349,176 |
| JardianceEmpagliflozin | 188 | $227,466 |
| TrulicityDulaglutide | 101 | $141,497 |
| SynthroidLevothyroxine Sodium | 1,014 | $112,907 |
| JanuviaSitagliptin Phosphate | 84 | $90,569 |
| MycapssaOctreotide Acetate | 13 | $86,587 |
| Teriparatide | 20 | $62,136 |
| Tresiba Flextouch U-200Insulin Degludec | 52 | $61,741 |
| ProliaDenosumab | 33 | $56,779 |
| Tresiba Flextouch U-100Insulin Degludec | 75 | $51,905 |
| KerendiaFinerenone | 56 | $45,372 |
| InvokanaCanagliflozin | 32 | $42,775 |
| TradjentaLinagliptin | 45 | $39,435 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 33 | $38,216 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $1,844 | $539,793456 claims |
| Novo NordiskOzempic | $2,016 | $349,176306 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr | $154 | $275,305244 claims |
| MerckJanuvia, Janumet Xr, Steglatro | $297 | $115,131122 claims |
| AbbVieSynthroid | $806 | $112,9071,014 claims |
| Chiesi USA, Inc.Mycapssa | $40 | $86,58713 claims |
| AmgenProlia | $1,102 | $56,77933 claims |
| BayerKerendia | $520 | $45,37256 claims |
| Johnson & JohnsonInvokana | $198 | $42,77532 claims |
| AstraZenecaFarxiga | $328 | $36,22030 claims |
| Antares Pharma, Inc.Xyosted | $842 | $28,39038 claims |
| IBSA Pharma Inc.Tirosint | $462 | $19,51573 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 952 endocrinology, diabetes & metabolism providers in California.
Other endocrinology, diabetes & metabolism in Los Gatos
- Juan FriasSan Diego$1.4M
- Joselito CabaccanSan Jose$1.4M
- Daniel NadeauNewport Beach$1.2M
- Yehuda HandelsmanTarzana$1M
- Helen BaronRancho Mirage$958K
- Ken FujiokaSan Diego$747K
- Minou TranPico Rivera$663K
- James ChuMonterey$639K
- Anthony HeaneyLos Angeles$588K
- Daniel Einhornla Jolla$578K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.